Detalhe da pesquisa
1.
Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling.
Cancer Res Commun
; 4(3): 738-756, 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315147
2.
Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Cells
; 10(11)2021 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34831127